|Bid||35.68 x 1000|
|Ask||58.33 x 1000|
|Day's Range||55.60 - 56.93|
|52 Week Range||33.97 - 57.28|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||31.88|
|Forward Dividend & Yield||0.19 (0.37%)|
|1y Target Est||N/A|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Ensign Group (ENSG) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Ensign Group (ENSG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.85% and -1.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Mission Viejo, California-based company said it had profit of 49 cents per share. Earnings, adjusted for one-time gains and costs, were 55 cents per share. The results exceeded Wall Street expectations. ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching The Ensign Group, Inc. (NASDAQ:ENSG) might want to consider the historical volatil...
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]
Moody's Investors Service ("Moody's") upgraded the corporate family rating of CareTrust REIT, Inc. ("CareTrust") to Ba2 from Ba3 and the senior unsecured rating of its subsidiary, CTR Partnership, L.P., to Ba2 from Ba3. The rating outlook was revised to stable from positive.
Ensign Group (ENSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While small-cap stocks, such as The Ensign Group, Inc. (NASDAQ:ENSG) with its market cap of US$2.7b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive...
Ensign Group Inc NASDAQ/NGS:ENSGView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ENSG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ENSG. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ENSG had net inflows of $1.69 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
According to the Centers for Medicare and Medicaid Services, healthcare spending in 2017 represented nearly 18% of U.S. GDP that year. And it projected that spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP -- a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 Biometric Stocks to Watch as AI Rises That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets. Healthcare Stocks: Masimo (MASI)Source: FlickrMasimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 59% in the past 12 months, and half of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like. Ionis Pharmaceuticals (IONS)Source: Shutterstock Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on.This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments. * The Elite 8 Stocks to Buy for Massive Outperformance IONS is already partnered with a number of larger pharmaceutical firms and is up 94% in the past year, with plenty of headroom left. Osiris Therapeutics (OSIR)Source: Shutterstock Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 118% for the year and 46% in 2019. Ensign Group (ENSG)Source: Shutterstock Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles.It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is. * 10 Tech Stocks That Transformed Their Business Up 94% in the past year, its size makes it a potential takeover target or a big grower on its own. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 112% in the past year and it's still going strong. National Research Corp (NRC)Source: Shutterstock National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research.While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Up 30% in the past year, NRC also delivers a near-2% dividend. AngioDynamics (ANGO)Source: Flickr>AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Up almost 20% in the past year, the future is bright. And its global potential is huge, as China looks to upgrade its entire healthcare system.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in aRead More...
Ensign Group (ENSG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A unit of Ensign Group's (ENSG) subsidiary buys the assets of All County Home Care and Hospice to boost its health and hospice portfolio.